SCHEMBL30002312

SCHEMBL30002312

CCOC(=O)c1cc(O)c2ccccc2n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.54
ALDH1A1 P00352 3/20 0.54
CYP1A2 P05177 2/20 0.53
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 4/20 0.50
KDM4E B2RXH2 3/20 0.50
ALOX15 P16050 1/20 0.50
CCR6 P51684 1/20 0.50
GLA P06280 1/20 0.50
POLB P06746 1/20 0.50
GAA P10253 2/20 0.48
NPY1R P25929 1/20 0.48
NPY2R P49146 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
GABRP O00591 1/20 0.48
GABRD O14764 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1733527 1.00 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1CYP1A2MEN1KMT2A
SCHEMBL6889759 0.87 ALDH1A1 (0.61) SMN1; SMN2ALDH1A1CYP1A2MEN1KMT2A
SCHEMBL20606425 0.85 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1CYP1A2MEN1KMT2A
SCHEMBL163381 0.84 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1CYP1A2MEN1KMT2A
SCHEMBL7720682 0.84 TDP1 (0.51) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL2222620 0.84 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1CYP1A2MEN1KMT2A
SCHEMBL3332188 0.84 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1CYP1A2MEN1KMT2A
SCHEMBL31389316 0.83 KDM4E (0.54) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL561686 0.83 KDM4E (0.54) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL13209979 0.83 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1CYP1A2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119215104-A Traditional Chinese medicine extract and application thereof in preparation of cell necrotic apoptosis inhibitor 河南中医药大学 2024-12-31 CN claimed
US-20250275954-A1 USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR UNIV JIMEI (CN) 2025-09-04 US disclosed
WO-2025107568-A1 USE OF KYNURENIC ACID IN RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARING XOD INHIBITOR 集美大学 2025-05-30 WO disclosed
CN-115887458-B Application of 4-hydroxy-2-quinoline carboxylic acid ethyl ester in preparation of medicines or reagents for promoting liver cell proliferation 集美大学 2025-01-07 CN disclosed
CN-119215104-A Traditional Chinese medicine extract and application thereof in preparation of cell necrotic apoptosis inhibitor 河南中医药大学 2024-12-31 CN disclosed
WO-2022214519-A1 ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275954-A1 USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR XDH, DAO, KMO SMN1; SMN2 4428/4885ALDH1A1 635/4885CYP1A2 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.